(A). Schematic representation of intracolonic injection of AAV encoding GFP or GFP-Cre into Piezo2fl/fl mice. (B). Schematic diagram showing the timing of AAV injection, zymosan treatment, and VMR recording. (C) Summary data showing that Piezo2AAV-DTA mice display significantly decreased zymosan-induced visceral hypersensitivity compared to Piezo2AAV-GFP mice. *P<0.05, **P<0.01, ***P<0.001. Two-way ANOVA, n=5 mice per group. (D) Summary data showing that neither Piezo2AAV-GFP nor Piezo2AAV-DTA mice display visceral hypersensitivity after vehicle treatment. n=4 mice per group (E). Schematic diagram showing the timing of AAV injection, PCO surgery, and VMR recording. (F) Summary data showing that Piezo2AAV-DTA mice display significantly decreased visceral hypersensitivity induced by PCO compared to Piezo2AAV-GFP mice. *P<0.05, ****P<0.0001. Two-way ANOVA, n=5 mice per group. (G) Summary data showing that neither Piezo2AAV-GFP nor Piezo2AAV-DTA mice display visceral hypersensitivity after sham surgery. n=4 mice per group. All data are expressed as mean ± S.E.